KYMR — Kymera Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.16bn
- $1.68bn
- $47.07m
- 47
- 13
- 28
- 19
Annual cashflow statement for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -45.6 | -100 | -155 | -147 | -224 |
| Depreciation | |||||
| Non-Cash Items | 7.09 | 30.8 | 36.4 | 37.9 | 46 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 125 | -61.9 | -37.6 | 2.68 | -24 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 88.1 | -129 | -153 | -103 | -195 |
| Capital Expenditures | -9.1 | -1.6 | -2.84 | -34.5 | -12.8 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -413 | -98.2 | 23.4 | 174 | -391 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -423 | -99.8 | 20.5 | 140 | -404 |
| Financing Cash Flow Items | 13.5 | 1.95 | 0 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 289 | 250 | 153 | 4.19 | 609 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -45.2 | 21.5 | 20.4 | 41.3 | 10.3 |